Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $2.00, $0.22 better than the analyst estimate of $1.78. Revenue for the quarter came in at $11 billion versus the consensus estimate of $10.98 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2023 EPS of $7.50-$7.65, versus the consensus of $7.36.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.